Intelligence · Clinical Development
Pipeline search results
Programs matching “Novartis” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 341 pipeline programs matching "Novartis" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Aliskiren
Novartis Pharmaceuticals
Hypertension
1 trial -
CAIN457I2401
Novartis Pharmaceuticals
non-radiographic axial spondyloarthritis
1 trial -
CDRB436G2401
Novartis Pharmaceuticals
Children and Adolescents with Cancers Harboring V600 mutation.
1 trial -
CDRB436X2X02B
Novartis Pharmaceuticals
Multiple indications
1 trial -
CELC200A2406
Novartis Pharmaceuticals
Parkinson's Disease
1 trial -
CERITINIB
Novartis Pharmaceuticals
non small cell lung cancer
1 trial -
CINC424A2X01B
Novartis Pharmaceuticals
This study is designed to accept patients with varied disease origins, depending on the parent protocol
1 trial -
CKJX839A12402
Novartis Pharmaceuticals
Hypercholesterolemia
1 trial -
CKJX839A1DE02
Novartis Pharmaceuticals
Hypercholesterolemia
1 trial -
CLEE011A2412B
Novartis Pharmaceuticals
HR+, HER2- advanced or metastatic breast cancer
1 trial -
CLNP023A2002B
Novartis Pharmaceuticals
IgA Nephropathy
1 trial -
Enteric-Coated Mycophenolate Sodium (EC-MPS)
Novartis Pharmaceuticals
Renal Transplant
1 trial -
Fluvirin(TIVf)
Novartis Pharmaceuticals
Influenza
1 trial -
IPTACOPAN HYDROCHLORIDE, IPTACOPAN
Novartis Pharmaceuticals
C3 Glomerulopathy or idiopathic immune-complex membranoproliferative glomerulonephritis
1 trial -
Indacaterol
Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
1 trial -
Kesimpta 20 mg solution for injection in pre-filled syringe
Novartis Pharmaceuticals
Relapsing forms of Multiple Sclerosis (RMS)
1 trial -
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals
Neovacular Age-related Macular Degeneration
1 trial -
Ofatumumab
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
1 trial -
Placebo of vildagliptin
Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
1 trial -
Pluvicto 1 000 MBq/mL solution for injection/infusion
Novartis Pharmaceuticals
Prostate cancer
1 trial -
Ribociclib
Novartis Pharmaceuticals
Metastatic Breast Cancer
1 trial -
Rivastigmine
Novartis Pharmaceuticals
Alzheimer's Disease
1 trial -
Rivastigmine transdermal patch
Novartis Pharmaceuticals
Alzheimer's Disease
1 trial -
SEG101
Novartis Pharmaceuticals
Sickle cell disease
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.